Emerging Nanomedicine Therapies to Counter the Rise of Methicillin-Resistant Staphylococcus aureus

Materials
Alan Hibbitts, Cian O'Leary

Abstract

In a recent report, the World Health Organisation (WHO) classified antibiotic resistance as one of the greatest threats to global health, food security, and development. Methicillin-resistantStaphylococcus aureus(MRSA) remains at the core of this threat, with persistent and resilient strains detectable in up to 90% ofS. aureusinfections. Unfortunately, there is a lack of novel antibiotics reaching the clinic to address the significant morbidity and mortality that MRSA is responsible for. Recently, nanomedicine strategies have emerged as a promising therapy to combat the rise of MRSA. However, these approaches have been wide-ranging in design, with few attempts to compare studies across scientific and clinical disciplines. This review seeks to reconcile this discrepancy in the literature, with specific focus on the mechanisms of MRSA infection and how they can be exploited by bioactive molecules that are delivered by nanomedicines, in addition to utilisation of the nanomaterials themselves as antibacterial agents. Finally, we discuss targeting MRSA biofilms using nano-patterning technologies and comment on future opportunities and challenges for MRSA treatment using nanomedicine.

References

May 1, 1981·JPEN. Journal of Parenteral and Enteral Nutrition·A Wretlind
May 21, 1999·Science·J W CostertonE P Greenberg
Jul 21, 2001·Lancet·P S Stewart, J W Costerton
Sep 21, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R M Donlan
Jul 1, 1961·Journal of Clinical Pathology·M BARBER
Jan 14, 2004·The Journal of Biological Chemistry·In Yup ParkSun Chang Kim
Nov 3, 2004·Carbohydrate Research·Lifeng QiXiangfei Zou
Dec 4, 2004·Nature Medicine·Stuart B Levy, Bonnie Marshall
Mar 2, 2005·Tissue Engineering·Kee W NgDietmar W Hutmacher
Nov 18, 2005·Toxicology Letters·Zhen ChenLijun Wan
Dec 14, 2005·The Journal of Antimicrobial Chemotherapy·Katsunori YanagiharaShigeru Kohno
Feb 4, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Neeloffer MookherjeeRobert E W Hancock
Dec 13, 2006·Nature Biotechnology·Robert E W Hancock, Hans-Georg Sahl
Mar 27, 2007·Nature Biotechnology·Monisha G ScottRobert E W Hancock
Apr 11, 2007·Bioorganic & Medicinal Chemistry Letters·Edward TurosDaniel V Lim
Feb 5, 2008·Biotechnology Journal·Natasa Mitik-DinevaElena P Ivanova
Jul 30, 2008·Archives of Internal Medicine·Adam L HershRalph Gonzales
Feb 3, 2009·Experimental and Molecular Pathology·Rajesh Singh, James W Lillard
Feb 19, 2009·Nanomedicine : Nanotechnology, Biology, and Medicine·Wiyong KangwansupamonkonUracha Ruktanonchai
Jul 8, 2009·Nature Nanotechnology·Lihong LiuYi-Yan Yang
Aug 12, 2009·Biomaterials·Jonathan LelloucheEhud Banin
Oct 22, 2009·Langmuir : the ACS Journal of Surfaces and Colloids·Elena P IvanovaRussell J Crawford
Nov 3, 2009·Biomaterials·Sabrina D PuckettThomas J Webster
Jan 2, 2010·The European Respiratory Journal·P Martínez-OlondrisA Torres
Jan 29, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Anastasia NijnikRobert E W Hancock
Jul 28, 2010·Archives of Orthopaedic and Trauma Surgery·Fei WangJun Liu
Oct 1, 2010·Biomaterials·Chun-Ming HuangLiangfang Zhang
Oct 19, 2010·International Journal of Food Microbiology·Ming KongHyun Jin Park
Dec 7, 2010·International Journal of Antimicrobial Agents·Andrew PumerantzGuru Betageri
Jan 14, 2011·Langmuir : the ACS Journal of Surfaces and Colloids·Thomas DelmasJérôme Bibette
Mar 16, 2011·Langmuir : the ACS Journal of Surfaces and Colloids·Krishna R RaghupathiAdhar C Manna
May 21, 2011·Journal of Colloid and Interface Science·Thomas DelmasIsabelle Texier
Jul 19, 2011·Journal of Controlled Release : Official Journal of the Controlled Release Society·Ae Jung Huh, Young Jik Kwon
Jul 27, 2011·Antimicrobial Agents and Chemotherapy·Krishna MuppidiAndrew S Pumerantz
Sep 17, 2011·Virulence·Karin BlecherAdam Friedman
Nov 15, 2011·Current Pharmaceutical Design·Vinsová Jarmila, Eva Vavríková
Mar 14, 2012·FEMS Immunology and Medical Microbiology·Deirdre Fitzgerald-HughesHilary Humphreys

❮ Previous
Next ❯

Citations

Feb 11, 2020·Drug Delivery·Samah Attia AlgharibShuyu Xie
Sep 9, 2020·Drug Development and Industrial Pharmacy·Mohammed M MehannaKhaled Abed El Jalil
Mar 21, 2020·Daru : Journal of Faculty of Pharmacy, Tehran University of Medical Sciences·Maria Hassan KianiGul Shahnaz
Jun 10, 2020·Drug Delivery and Translational Research·Magda FerreiraMaria Manuela Gaspar
Jun 3, 2021·Animals : an Open Access Journal From MDPI·Andra Sabina Neculai-ValeanuŞteofil Creangă

❮ Previous
Next ❯

Methods Mentioned

BETA
antisense oligonucleotides
transfection
SELEX

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Biofilms

Biofilms are adherent bacterial communities embedded in a polymer matrix and can cause persistent human infections that are highly resistant to antibiotics. Discover the latest research on Biofilms here.

Biofilm & Infectious Disease

Biofilm formation is a key virulence factor for a wide range of microorganisms that cause chronic infections.Here is the latest research on biofilm and infectious diseases.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Nihon rinsho. Japanese journal of clinical medicine
Junichi YoshidaKenji Kono
Nihon rinsho. Japanese journal of clinical medicine
Teruyo Ito, Keiichi Hiramatsu
© 2022 Meta ULC. All rights reserved